Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Nintedanib · 1 trial · 1 indication
| Name | Type | Description |
|---|---|---|
| Nintedanib 150 MG [Ofev] | DRUG | Nintedanib 150 MG will be administered every 12 hours from Days 1 to 20. LYT-100 will be titrated from 275 MG three times a day on Days 8 to 10, to 550 MG three times a day on Days 11 to 13, to 825 MG three times a day on Days 14 to 30. |
Nintedanib is a small molecule being studied in the context of drug interactions. A completed Phase 1 trial evaluated the potential for drug-drug interactions when co-administering deupirfenidone (LYT-100) and nintedanib. The trial enrolled 24 participants and focused on the condition of drug interactions.
Nintedanib is being developed by PureTech Health plc, which trades under the ticker PRTC. The company is conducting clinical research on this small molecule, including a Phase 1 study to assess its interactions with other drugs.
Nintedanib is in Phase 1 clinical development. It is an investigational drug and has not been approved by regulatory authorities. One Phase 1 trial has been completed, with no active trials currently listed.
Nintedanib has one completed clinical trial, identified as NCT06717100. This Phase 1 study was designed to determine the potential for drug-drug interactions when co-administering deupirfenidone (LYT-100) and nintedanib. The trial enrolled 24 participants and was not randomized or double-blinded.
No, Nintedanib is not the same as deupirfenidone. They are distinct drugs that were studied together in a clinical trial to assess potential drug-drug interactions. The trial, NCT06717100, evaluated the effects of co-administering these two medications.